

October 28, 1998

Endo Pharmaceuticals Inc.  
Attention: Andrew G. Clair, Ph.D.  
500 Endo Boulevard  
Garden City, NY 11530



Dear Sir:

This is in reference to your abbreviated new drug application dated December 30, 1997, submitted pursuant to Section 505(j) of the Federal Food, Drug, and Cosmetic Act, for Morphine Sulfate Extended-release Tablets, 15 mg, 30 mg and 60 mg.

Reference is also made to your amendments dated June 15, June 23, July 30, August 24, September 1, September 24, and October 5, 1998.

We have completed the review of this abbreviated application and have concluded that the drug is safe and effective for use as recommended in the submitted labeling. Accordingly, the application is approved. The Division of Bioequivalence has determined your Morphine Sulfate Extended-release Tablets, 15 mg, 30 mg and 60 mg, to be bioequivalent and, therefore, therapeutically equivalent to the listed drug (MS Contin Tablets, 15 mg, 30 mg, and 60 mg, respectively, of Purdue Frederick Co.). Your dissolution testing should be incorporated into the stability and quality control program using the same method proposed in your application. The "interim" dissolution test and tolerances are:

The dissolution testing should be conducted in 500 mL of water at 37°C using USP XXIII apparatus II (paddle) at 50 rpm. The test product should meet the following interim specifications:

- 1 hr
- 2 hr
- 4 hr
- 8 hr

The "interim" dissolution test and tolerances should be finalized by submitting dissolution data for the first three production size batches in a supplemental application. The supplemental application should be submitted under 21 CFR 314.70 (c)(1) when there are no revisions to the interim specifications or when the final specifications are tighter than the interim specifications. In all other instances the supplement should be submitted under 21 CFR 314.70 (b)(2)(ii).

Under 21 CFR 314.70, certain changes in the conditions described in this abbreviated application require an approved supplemental application before the change may be made.

Post-marketing reporting requirements for this abbreviated application are set forth in 21 CFR 314.80-81 and 314.98. The Office of Generic Drugs should be advised of any change in the marketing status of this drug.

We request that you submit, in duplicate, any proposed advertising or promotional copy which you intend to use in your initial advertising or promotional campaigns. Please submit all proposed materials in draft or mock-up form, not final print. Submit both copies together with a copy of the proposed or final printed labeling to the Division of Drug Marketing, Advertising, and Communications (HFD-40). Please do not use Form FD-2253 (Transmittal of Advertisements and Promotional Labeling for Drugs for Human Use) for this initial submission.

We call your attention to 21 CFR 314.81(b)(3) which requires that materials for any subsequent advertising or promotional campaign be submitted to our Division of Drug Marketing, Advertising, and Communications (HFD-40) with a completed Form FD-2253 at the time of their initial use.

Sincerely yours,

Douglas L. Sporn  
Director  
Office of Generic Drugs  
Center for Drug Evaluation and Research